No association between NOS2 and NOS3 polymorphisms and diabetic nephropathy in type 2 diabetics 
Introduction
Diabetic nephropathy (diabetic kidney disease, DN) is associated with high morbidity and mortality, mainly due to cardiovascular disease (CVD). It is defined as a rise in urinary albumin excretion rate, often associated with an increase in blood pressure and concomitant retinopathy but without evidence of other causes of renal disease. There is growing evidence for a genetic susceptibility to DN, presumably being a complex, polygenic disease that develops after exposure to environmental factors [1, 2] . Under normal physiological conditions in the kidney, nitric oxide (NO) participates in the regulation of the glomerular microcirculation by modulating afferent arteriolar tonus and relaxation of the mesangium cells and contributes to the regulation of renal sodium and renin release. Reducing the NO levels by inhibition of the NO-generating enzymes resulted in glomerular disease and systemic as well as glomerular hypertension in animal models, suggesting a renoprotective role for NO [rev. in 3,4] . However, the role of NO in diabetes is complex. On one hand, NO inhibits inflammatory-proliferative reactions in vascular wall cells and exerts anti-thrombogenic and endothelial cell protective properties, but it can also be involved in pro-inflammatory reactions and tissue damage [5] . In the pathogenesis of DN, it was suggested early stages of DN are associated with increased intrarenal NO production, contributing to hyperfiltration and microalbuminuria. On the other hand, advanced DN is related to a state of progressive NO deficiency [rev. in 3,4] .
NO is synthesized by a family of enzymes called NO synthases (NOS). There are three mammalian NOS isoforms that share 50-60% homology at the amino acid level. In contrast to inducible NOS (iNOS), neuronal (nNOS) and endothelial (eNOS) are generally known to continuously synthesize NO. Rather than being a constitutive enzyme as was first suggested, eNOS is dynamically regulated at the transcriptional, posttranscriptional, and posttranslational levels [rev. in 4, 6] . It can generate superoxide rather than NO under conditions of substrate or co-factor deficiency or in response to atherogenic stimuli (NOS uncoupling), adding to increased oxidative stress [rev. in 7] . Diabetic animal models suggest the endogenous availability of eNOS may be a key determinant for the development of nephropathy [8] [9] [10] . However, they also point towards the importance of iNOS in diabetic pathophysiologydecreased expression of eNOS was concomitant with increased expression of iNOS and nitrotyrosine during the progression of diabetes in rats [11] . Induction of iNOS in cardiovascular tissues contributes significantly to the depressed pressor responses to vasoactive agents and potentially to endothelial dysfunction [rev. in 6] .
To investigate the impact of genetic polymorphisms possibly affecting eNOS and iNOS function on DN development, we analyzed the association of eNOS Glu298Asp (rs1799983), eNOS 4a/b and iNOS Ser608Leu (rs2297518) polymorphisms in T2D patients. Selected genotype status was compared to serum 8-OHdG (8-hydroxy-2-deoxyguanosine), one of the predominant forms of free radical-induced oxidative lesions in nuclear and mitochondrial DNA. It has therefore been widely used as a biomarker for oxidative stress and carcinogenesis [rev. in 12].
Experimental Procedures

Patients and study design
198 unrelated Slovenian (Caucasian) T2D patients, age 34-83, were included in this cross-sectional study and stratified into two groups according to the presence of DN: a study group of 88 patients with DN (DN+) and a control group of 109 patients without DN but type 2 diabetes lasting over 10 years (DN-). Diagnosis of diabetes and DN was made according to WHO (World Health Organization) 1999 diagnostic criteria [13] . To avoid the confounding effect of impaired kidney function, patients with overt nephropathy were not enrolled in the study. Patients with poor glycaemic control, significant heart failure (NYHA II-IV), alcoholism, infection and other causes of renal disease were also excluded. The study was approved by the national medical ethics committee. All patients signed an informed consent for participation in the study and were interviewed in person. Information on smoking, presence and family history of CVD, duration of arterial hypertension and diabetes, diabetes management and complications (retinopathy, neuropathy, diabetic foot), therapy and routine laboratory measurements were obtained from their medical records.
DNA isolation and genotyping
DNA was extracted from peripheral blood samples using a commercial isolation kit according to manufacturer's protocol (DNeasy Blood & Tissue Kit, Qiagen). The eNOS 4a/b polymorphism was tested using PCR as described previously by Wang et al. [14] . The eNOS Glu298Asp and iNOS Ser608Leu polymorphisms were analyzed using real-time PCR (qPCR) method with protocols in Table 1 ; both assays were designed by Applied Biosystems by Life Technologies. Genotyping was performed in a 48-well StepOne™ Real-Time PCR instrument by two researchers, blinded for case or control status of the patients.
Serum 8-OHdG
Levels of 8-OHdG, a reliable DNA damage marker [rev. in 12], was used to assess oxidative stress and was measured by enzyme-linked immunosorbent assay (ELISA).
Statistical analysis
Statistical analysis was performed using SPSS version 17.0 software. Numeric variables are reported as mean ± standard deviation (SD); variance between both groups was assessed using ANOVA. Chi-square test was used to compare categorical variables. Genotypes were tested for Hardy-Weinberg equilibrium among DN+ and DN-groups. Finally, a multivariate logistic regression model was performed for the risk factors and genotypes with respect to DN. A P value of <0.05 was considered statistically significant.
Results and Discussion
Susceptibility to DN is most likely determined by a large number of relatively common allelic variants, possibly interlinked and interacting with environmental influences. Known risk factors for developing DN (duration of diabetes, older age, male sex, smoking, and poor glycaemic control [15] ) were at least partly confirmed by our results ( Table 2) with differences resulting from our in/exclusion criteria. Due to the cross-sectional study design, reflecting the actual diabetic population, DN+ and DN-groups were not matched for other factors and therefore the observed significant differences in gender, glycaemic control, lipid status and CVD are expected. Differences in parameters reflecting kidney function (serum creatinine, cystatin C, eGFR and urine albumine/ creatinine ratio) confirm chronic kidney disease in DN+ group. Importantly, there was no significant difference between groups regarding blood pressure, which is also a substantial contributor to renal dysfunction. Finally, all unmatched variables and all important risk factors (gender, duration of T2D and hypertension, SBP, DBP, BMI, smoking, fasting glucose, HbA1c, total cholesterol, HDL, serum creatinine, cystatin C, eGFR, urine albumine/creatinine ratio) were tested with respect to DN in a multivariate logistic regression model. Significant association with DN was confirmed for male gender (P=0.008), duration of T2D (P<0.001), cystatin C (P=0.043), HbA1c (P=0.012) and CVD (P=0.037).
As for the genetic component, we selected 3 polymorphic variants that could hypothetically affect the function of NO-producing enzymes, influencing NO accessibility and consequently oxidative stress level. In general, increased nitrosative stress is linked to increased oxidative stress [rev. in 16]. 8-OHdG is a reliable oxidative stress marker, but there is no consensus on what the true levels are in human DNA [17] . Comparison of serum 8-OHdG by Al-Aubaidy and Jelinek [18] showed a significant increase from healthy (177.8 pg/ml) to prediabetic (516.5 pg/ml) and finally diabetic individuals (1926.9 pg/ml). Studies also show a significant increase in diabetic nephropathy in comparison to diabetes without vascular complications, especially in patients with proteinuria greater than 3g/day [19, 20] . Our 8-OHdG measurements showed no significant difference between DN+ (15920±10.81 pg/ml) and DN-(15020±4.31 pg/ml) groups (P=0.7); possibly due to exclusion of patients with overt nephropathy.
We tested two commonly reported eNOS (NOS3) polymorphisms that have been related to DN in a HuGE review and meta-analysis: the NOS3 4a/b and the NOS3 Glu298Asp (rs1799983) [21] . NOS3 4a/b polymorphism is a 27bp repeat (allele a -deletion with four tandem 27-bp repeats, allele b -insertion having five repeats) in intron 4. In addition to DN the NOS3 4a/b polymorphism has also been related to diabetic retinopathy [22] . It was suggested that given the intronic location of this polymorphism it is less likely to be functional. Considering the opposing results regarding protein expression and NO plasma levels in carriers, it is possible the variant is in linkage disequilibrium with other functional variants in regulatory regions of the NOS3 gene [23] . NOS3 Glu298Asp (rs1799983) is a missense mutation, in which a guanine to thymine (G/T) substitution at exon 7 leads to a glutamate to aspartate substitution at position 298. According to computer modelling the polymorphism might affect the protein-protein interactions and localization of eNOS [24] . Studies also indicate the polymorphic protein products differ in susceptibility to protein cleavage [25] , but the functional role of this polymorphism is not yet resolved [rev. in 23] . In previous studies, the Asp allele was associated with reduced basal NO production and/or Table 2 . Population characteristics. decreased NOS activity [26] [27] [28] . In addition to DN it has also been associated to end stage renal disease (ESRD), both diabetes-and hypertension-derived [29] . Nevertheless, the previously mentioned metaanalysis showed high heterogeneity between studies and concluded eNOS polymorphisms individually are unlikely to make a useful contribution to risk prediction in asymptomatic persons [21] . In our study, the comparison of the NOS3 4a/b genotype and allele distributions in DN+ and DN-groups could not confirm the association of this polymorphism with DN, neither could we confirm the association between distinct NOS3 4a/b genotypes and oxidative stress level (Tables 3 and 4) . However, our results show a higher percentage of b/b genotype in comparison to another study comprising Slovenian population [30] . Taken together, our results suggest a possible role of this polymorphism in T2D development rather than DN in (Table 3 ). The observed genotype frequencies are similar to the previously published in the neighbouring Italian population [31] . There was also no association between NOS3 Glu298Asp genotypes and oxidative stress level (Table 4) . iNOS Ser608Leu missense polymorphism (C/T) in exon 16 (rs2297518) might also be of functional interest, but it has not yet been tested for association with DN. It has been reported to have an affect on enzymatic activity and has been associated to T1D in a subset of T1D patients [32] . Leu/Leu homozygotes have been reported to confer higher enzymatic activity and iNOS expression resulting in increased NO production and inflammation [rev in 33]. Our results are consistent with previous findings in terms of genotype distributions being similar to those of control groups in other studies [33] [34] [35] . There was no significant difference in genotype and allele frequencies between our DN-and DN+ groups (Table  3 ). However, we found an increase in oxidative stress level in TT (Leu/Leu) patients (Table 4) , which was significant in DN+ group and the combined (DN+ and DN-) group, but not DN-group. These results suggest a possible role of TT (Leu/Leu) genotype in advanced DN. Nevertheless, multivariate logistic regression analysis revealed no association between individual genotype variants and DN. There was also no correlation between genotypes and the above mentioned DN+/DN-unmatched variables and known DN risk factors.
SBP = sistolic blood pressure, DBP = diastolic blood pressure, BMI = body mass index, CVD = cardiovascular disease, DR = diabetic retinopathy, DNeur = diabetic neuropathy, DF = diabetic foot, eGFR -estimated glomerular filtration rate, HDL = high-density lipoprotein, LDL = low-density lipoprotein, S-= serum, TG = triglycerides, U-= urine
In conclusion, we failed to demonstrate the association between the selected eNOS and iNOS genetic polymorphisms and DN. Our results reflect the multifactorial nature of DN in addition to genetic heterogeneity within and between the populations.
